Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celularity (CELU) EBIT (2020 - 2025)

Celularity has reported EBIT over the past 6 years, most recently at -$12.9 million for Q3 2025.

  • Quarterly results put EBIT at -$12.9 million for Q3 2025, down 11.91% from a year ago — trailing twelve months through Sep 2025 was -$48.5 million (down 207.87% YoY), and the annual figure for FY2024 was -$38.4 million, up 80.05%.
  • EBIT for Q3 2025 was -$12.9 million at Celularity, up from -$15.9 million in the prior quarter.
  • Over the last five years, EBIT for CELU hit a ceiling of $17.5 million in Q4 2022 and a floor of -$99.3 million in Q3 2023.
  • Median EBIT over the past 5 years was -$11.5 million (2024), compared with a mean of -$21.3 million.
  • Peak annual rise in EBIT hit 326.76% in 2021, while the deepest fall reached 29007.3% in 2021.
  • Celularity's EBIT stood at -$15.0 million in 2021, then soared by 216.95% to $17.5 million in 2022, then decreased by 23.85% to $13.3 million in 2023, then crashed by 169.7% to -$9.3 million in 2024, then crashed by 39.01% to -$12.9 million in 2025.
  • The last three reported values for EBIT were -$12.9 million (Q3 2025), -$15.9 million (Q2 2025), and -$10.5 million (Q1 2025) per Business Quant data.